Sudha Seshadri1,2, Emelia J Benjamin1,3,4, Faisal Rahman5, Jayandra J Himali1,2, Xiaoyan Yin1,6,3, Alexa S Beiser1,2,6, Patrick T Ellinor7, Steven A Lubitz7, Ramachandran S Vasan1,3,4, Jared W Magnani8, David D McManus1,9,10. 1. National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA, USA. 2. Department of Neurology, Boston University School of Medicine, Boston, MA, USA. 3. Section of Cardiovascular Medicine, Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. 4. Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. 5. Department of Medicine, Boston University Medical Center, Boston, MA, USA. 6. Department of Biostatistics, Boston University, Boston, MA, USA. 7. Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA, USA. 8. Department of Medicine, Division of Cardiology, UPMC Heart & Vascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. 9. Departments of Medicine and Quantitative Health Sciences, University of Massachusetts, Worcester, MA, USA. 10. Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA, USA.
Abstract
Brain-derived neurotrophic factor (BDNF) is expressed by endothelial cells and can affect cardiovascular function. We examined if serum BDNF was associated with risk of incident atrial fibrillation (AF) in the Framingham Heart Study. METHODS: We studied individuals without an AF diagnosis at baseline from the Framingham original and offspring cohorts. We used age- and sex-adjusted, and multivariable-adjusted Cox proportional hazards regression models to examine the association of serum BDNF concentrations with 10-year risk of incident AF. RESULTS: We studied 3,457 participants (mean age 65±11years, 58% women). During follow-up, 395 participants developed AF. In unadjusted analysis, higher mean serum BDNF concentration was associated with lower incidence of AF (hazard ratio 0.89 per SD, 95% CI 0.80-0.99). In multivariable-adjusted analyses, serum BDNF concentration was not significantly associated with incident AF (hazard ratio 0.98 per SD, 95% CI 0.88-1.09). Compared with the lowest quartile, BDNF levels in the other quartiles were not associated with risk of AF in multivariable-adjusted analyses. No interactions between sex or age with serum BDNF concentrations and risk of AF were found. CONCLUSIONS: In our prospective, community-based sample, we did not find a statistically significant association of serum BDNF levels with risk of incident AF.
Brain-derived neurotrophic factor (BDNF) is expressed by endothelial cells and can affect cardiovascular function. We examined if serum BDNF was associated with risk of incident atrial fibrillation (AF) in the Framingham Heart Study. METHODS: We studied individuals without an AF diagnosis at baseline from the Framingham original and offspring cohorts. We used age- and sex-adjusted, and multivariable-adjusted Cox proportional hazards regression models to examine the association of serum BDNF concentrations with 10-year risk of incident AF. RESULTS: We studied 3,457 participants (mean age 65±11years, 58% women). During follow-up, 395 participants developed AF. In unadjusted analysis, higher mean serum BDNF concentration was associated with lower incidence of AF (hazard ratio 0.89 per SD, 95% CI 0.80-0.99). In multivariable-adjusted analyses, serum BDNF concentration was not significantly associated with incident AF (hazard ratio 0.98 per SD, 95% CI 0.88-1.09). Compared with the lowest quartile, BDNF levels in the other quartiles were not associated with risk of AF in multivariable-adjusted analyses. No interactions between sex or age with serum BDNF concentrations and risk of AF were found. CONCLUSIONS: In our prospective, community-based sample, we did not find a statistically significant association of serum BDNF levels with risk of incident AF.
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: Alanna M Chamberlain; Sunil K Agarwal; Aaron R Folsom; Elsayed Z Soliman; Lloyd E Chambless; Richard Crow; Marietta Ambrose; Alvaro Alonso Journal: Am J Cardiol Date: 2011-01 Impact factor: 2.778
Authors: Galit Weinstein; Alexa S Beiser; Seung Hoan Choi; Sarah R Preis; Tai C Chen; Demetrios Vorgas; Rhoda Au; Aleksandra Pikula; Philip A Wolf; Anita L DeStefano; Ramachandran S Vasan; Sudha Seshadri Journal: JAMA Neurol Date: 2014-01 Impact factor: 18.302
Authors: Renate B Schnabel; Xiaoyan Yin; Philimon Gona; Martin G Larson; Alexa S Beiser; David D McManus; Christopher Newton-Cheh; Steven A Lubitz; Jared W Magnani; Patrick T Ellinor; Sudha Seshadri; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin; Daniel Levy Journal: Lancet Date: 2015-05-07 Impact factor: 79.321
Authors: Alvaro Alonso; Bouwe P Krijthe; Thor Aspelund; Katherine A Stepas; Michael J Pencina; Carlee B Moser; Moritz F Sinner; Nona Sotoodehnia; João D Fontes; A Cecile J W Janssens; Richard A Kronmal; Jared W Magnani; Jacqueline C Witteman; Alanna M Chamberlain; Steven A Lubitz; Renate B Schnabel; Sunil K Agarwal; David D McManus; Patrick T Ellinor; Martin G Larson; Gregory L Burke; Lenore J Launer; Albert Hofman; Daniel Levy; John S Gottdiener; Stefan Kääb; David Couper; Tamara B Harris; Elsayed Z Soliman; Bruno H C Stricker; Vilmundur Gudnason; Susan R Heckbert; Emelia J Benjamin Journal: J Am Heart Assoc Date: 2013-03-18 Impact factor: 5.501
Authors: Chintan N Koyani; Werner Windischhofer; Christine Rossmann; Ge Jin; Sandra Kickmaier; Frank R Heinzel; Klaus Groschner; Ali Alavian-Ghavanini; Wolfgang Sattler; Ernst Malle Journal: Int J Cardiol Date: 2014-03-20 Impact factor: 4.164